Shuttle Pharmaceuticals Holdings (SHPH): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
No concentrated manager holds it.
Who owns Shuttle Pharmaceuticals Holdings?
Hrt Financial Lp is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were HRT Financial (1.3% of the shares), Citadel Advisors (0.4%) and Barclays (0.0%).
Which institutions hold the most Shuttle Pharmaceuticals Holdings shares?
Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:
- 1. HRT Financial: 1.3%
- 2. Citadel Advisors: 0.4%
- 3. Barclays: 0.0%
- 4. Tower Research Capital LLC (TRC): 0.0%
- 5. Kelleher Financial Advisors: 0.0%
How much of Shuttle Pharmaceuticals Holdings do institutions own?
The 5 institutions that file 13F reported 1.8% of the shares as of Jun 30, 2026.
Sources:All of the company's proxy statements on EDGAR ↗
13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 15, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since December 2024: a holder above 5% that has not filed since then does not appear here.
Quarter flow (concentrated managers)
Concentrated managers holding it
None in the latest quarter.
Largest holders of SHPH (all 13F filers)
- HRT Financial79 KBank or trading desk · 1.65% of the company+79 K
- Citadel Advisors24 KQuant or multi-manager · 0.51% of the company+24 K
- Barclays750Bank or trading desk · 0.02% of the company+750
- Tower Research Capital LLC (TRC)389Type not verified · 0.01% of the company+389
- Kelleher Financial Advisors120Type not verified · 0.00% of the company+120
- Shares
- 79 K
- Change
- +79 K
- % of the company
- 1.65%
See more
- Type
- Bank or trading desk
- Value
- $255K
- Shares
- 24 K
- Change
- +24 K
- % of the company
- 0.51%
See more
- Type
- Quant or multi-manager
- Value
- $79.2K
- Shares
- 750
- Change
- +750
- % of the company
- 0.02%
See more
- Type
- Bank or trading desk
- Value
- $2.4K
- Shares
- 389
- Change
- +389
- % of the company
- 0.01%
See more
- Type
- Type not verified
- Value
- $1.3K
- Kelleher Financial Advisors
- Shares
- 120
- Change
- +120
- % of the company
- 0.00%
See more
- Type
- Type not verified
- Value
- $390
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Held by institutions (13F)
Institutions (13F): 1.8% of the shares · top 10: 1.8%
Shares reported by the 5 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (May 15, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.
Fundamentals
12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.
- Operating margin
- —
- Net margin
- —
- ROE
- -53.5%
- Revenue (TTM)
- —
- Revenue growth
- —
- Net income (TTM)
- $-10.3M
- Net debt / EBITDA
- —
- Free cash flow (TTM)
- —
- Quality vs sector
- —
This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.
Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated
Shares outstanding: buybacks and dilution
2025: 1.6 M
There is a jump that may be an undetected split: we do not show the changes.
- Buybacks (FY 2025)
- no data
- Share issuance
- no data
- Stock-based compensation
- $933K
- Dividends paid
- no data
From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.
Earnings quality and debt
- Operating cash flow ÷ net income (12 months)
- no datanot calculated with negative net income
- Debt due within 12 months
- no data
From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.
Insiders (Form 4)
10% owners who bought (6 m): 1 · $182K
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
This list may be incomplete: we hold 13D and 13G filings made since December 2024. A holder above 5% that has not filed anything since then is not shown here.
No recent filings.
Flagged material events (8-K)
Notice of delisting or failure to meet a listing rule (Item 3.01)
«Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter»
Notice of delisting or failure to meet a listing rule (Item 3.01)
Change of auditor (Item 4.01)
Exit or restructuring costs (Item 2.05)
Unregistered sale of equity securities (Item 3.02)
Unregistered sale of equity securities (Item 3.02)
Change in directors or officers (Item 5.02)
Unregistered sale of equity securities (Item 3.02)
«Shuttle Merges with United Dogecoin to Become the World’s Largest Public Dogecoin Miner»
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers